Pharsight Builds Momentum in DMX(R) Product, Signs deCODE genetics
MOUNTAIN VIEW, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST - News), a leading provider of software and strategic services for optimizing clinical drug development, recently announced that deCODE genetics, a leading biopharmaceutical company, has become a customer for the Drug Model Explorer (DMX). The license agreement with deCODE is the latest Pharsight has closed with leading pharmaceutical companies in Europe and the United States.
DMX is a software tool that allows clinical drug development teams to quickly and efficiently explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies.
"We hope to use DMX to drive faster and more confident drug-development decisions at deCODE," said David Hermann, PharmD, Executive Director of Pharmacometrics at deCODE. "We expect to use DMX to rapidly display our latest modeling results and make our development decisions clear to the entire team."
Daniel L. Hartman, M.D., Senior Vice President of Product Development at deCODE added, "Quantitative modeling and simulation offers a valuable set of approaches to help navigate the myriad trade-offs and complexities that inform key program decisions. We look forward to using DMX to explore model-based results and support the decision-making process for promising therapies in our pipeline."
About DMX
DMX can enhance the entire development team's understanding of a drug's likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process.
"DMX's intuitive presentation of modeling insights is especially useful when a new drug faces tough competition," said Shawn O'Connor, Pharsight president and chief executive officer. "We are pleased that deCODE recognizes the contribution that quantitative drug-disease modeling, combined with novel visualization and communication technology like DMX, can make to improve decision-making."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at pharsight.com . |
